MOUNTAINSIDE, NJ--(Marketwire - January 29, 2009) -
Highlighted Links |
|
|
Proteonomix, Inc. (PINKSHEETS: PROT) has announced that Terry Dubrow, M.D. has joined the Company as a consultant to represent it and Proteoderm, Inc., its subsidiary, as its medical spokesperson.
Dr. Dubrow is Board certified in general and plastic surgery and has maintained a private practice for ten years. While his practice includes many types of plastic surgery, Dr. Dubrow specializes in early-intervention rejuvenation procedures for optimal results requiring lower cost and less time. He also believes in minimal treatment and natural, “invisible plastic surgery results.”
Dr. Dubrow has written over 30 published papers many of which have appeared in plastic surgery journals. A graduate of the University of California School of Medicine and Yale University, he has been a Research Fellow in plastic surgery and is a member of the American Board of Plastic Surgery and other medical societies. Dr. Dubrow is a frequent participant on the popular Fox reality television show, “The Swan,” which is shown in 57 countries worldwide.
Michael Cohen, CEO of Proteonomix, stated: “We are extremely pleased to have the Dr. Dubrow join our company. We believe his impressive medical and surgical background make him an ideal spokesperson for us. Dr. Dubrow will represent the Company to governments and regulatory authorities, the media, shareholders and the general public, and will help to implement a long-term strategy for Proteoderm. Dr. Dubrow will also represent Proteoderm at various events and will be a liaison between us and the public. We are looking forward to working with Dr. Dubrow as we move forward to market our cosmetic products.”
Dr. Dubrow stated: “I am very excited to become part of such a vital, growing company with a line of stem cell-derived anti-aging cosmetic products headed to market. As a plastic surgeon who espouses subtle surgical treatment, I am particularly impressed with Proteoderm’s line of cosmoceuticals, which may revolutionize the skin care industry by rejuvenating patients’ skin while reducing the need for invasive procedures.”
About Proteonomix, Inc.
Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging cosmetics. For more information, please visit www.proteonomix.com or www.proteoderm.com and www.pinksheets.com.
“Safe Harbor Statement”
Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company’s expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.
Contact:
Michael Cohen
President
Proteonomix, Inc.
Phone: (973) 544-6116
Email Contact